Ignite Creation Date:
2025-12-24 @ 5:12 PM
Ignite Modification Date:
2026-04-10 @ 7:12 PM
Study NCT ID:
NCT00441350
Status:
COMPLETED
Last Update Posted:
2021-07-28
First Post:
2007-02-27
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
Sponsor:
Menarini Group
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CS866CM-B-E303
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |